Aspirin hypersensitivity in patients with chronic rhinosinusitis and nasal polyposis: Frequency and contributing factors

American Journal of Rhinology and Allergy

Volumn 28, Issue 3, 2014, Pages 239-243

  Nabavi, Mohammad ^a   Esmaeilzadeh, Hossein ^a,b   Arshi, Saba ^a   Bemanian, Mohammad Hassan ^a   Fallahpour, Morteza ^a   Bahrami, Ahmad ^a   Mortazavi, Negar ^c   Kamrava, Kamran ^d   Farhadi, Mohammad ^d   Taghipour, Reza ^a   Rezaei, Nima ^b,e  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; CORTICOSTEROID; IMMUNOGLOBULIN E; MONTELUKAST;

ADULT; ALLERGY; ARTICLE; ASTHMA; ATOPY; CHRONIC RHINOSINUSITIS; CLINICAL EVALUATION; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; NOSE SMEAR; PRICK TEST; PROVOCATION TEST; RISK ASSESSMENT; SCORING SYSTEM; SELF REPORT; SKIN; ASTHMA, ASPIRIN-INDUCED; CHRONIC DISEASE; IMMUNOLOGY; IRAN; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREVALENCE; RHINITIS; RISK FACTOR; SINUSITIS;

ADMINISTRATION, ORAL; ADULT; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IRAN; MALE; MIDDLE AGED; PREVALENCE; RHINITIS; RISK FACTORS; SINUSITIS;

EID: 84900556732     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2014.28.4034     Document Type: Article

References (33)

1. Hamilos DL. Chronic rhinosinusitis: Epidemiology and medical management. J Allergy Clin Immunol 128:693-707, 2011.
2. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasalpolyps. Rhinol Suppl 23:1-298, 2012.
3. Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: Definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 129(suppl):S1-S32, 2003.
4. Tan BK, Chandra RK, Pollak J, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol 131:1350-1360, 2013.
5. Chang JE, White A, Simon RA, and Stevenson DD. Aspirin-exacerbated respiratory disease: Burden of disease. Allergy Asthma Proc 33:117-121, 2012.
6. Mullol J, and Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am 33:163-176, 2013.
7. Szczeklik A, Nizankowska E, and Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 16:432-436, 2000.
8. Samter M, and Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 68:975-983, 1968.
9. Stevenson DD, and Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy ClinImmunol 118:773-786, 2006.
10. Graefe H, Roebke C, Dirk Schäfer D, and Meyer JE. Aspirin sensitivity and chronic rhinosinusitis with polyps: A fatal combination. J Allergy 817910, 2012.
11. Szczeklik A, Nizankowska-Mogilnicka E, and Sanak M. Hypersensitivity to aspirin and non-steroidal anti-inflammatory drugs. In Middleton's allergy: Principles and practice, 7th ed. Adkinson NF Jr, Bochner BS, Busse WW, et al. (Eds). New York NY: Mosby, 227-240, 2009.
12. Lee RU, and Stevenson DD. Aspirin-exacerbated respiratory disease: Evaluation and management. Allergy Asthma Immunol Res 3:3-10, 2011.
13. Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 9:155-163, 2009.
14. Jenkins C, Costello J, and Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 328:434, 2004.
15. Bavbek S, Dursun B, Dursun E, et al. The prevalence of aspirin hypersensitivity in patients with nasal polyposis and contributing factors. Am J Rhinol Allergy 25:411-415, 2011.
16. Berges-Gimeno MP, Simon RA, and Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89:474-478, 2002.
17. Lund VJ, and Kennedy DW. Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol 167:17-21, 1995.
18. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. National Heart and Blood Institute/World Health Organization (NHLBI/WHO) workshop report. NIH Publication 02-3659, Bethesda, MD, issued 1995, updated 2007.
19. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/GA2LEN guideline: Aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 62:1111-1118, 2007.
20. Macy E, Bernstein JA, Castells MC, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: A practice paper. Ann Allergy Asthma Immunol 98:172-174, 2007.
21. Hope AP, Woessner KA, Simon RA, and Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 123:406-410, 2009.
22. Hedman J, Kaprio J, Poussa T, and Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 28:717-722, 1999.
23. Kasper Ł, Sładek K, Bochenek G, et al. The frequency of hypersensitivity to non-steroidal antiinflammatory drugs (NSAIDs) in the population of adult asthmatics in Poland based on an epidemiological questionnaire. Pneumonol Alergol Pol 77:431-439, 2009.
24. Bavbek S, Yilmaz I, Celik G, Aydin O, et al. Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: A cross-sectional survey. Allergol Immunopathol (Madr) 40:225-230, 2012.
25. Fan Y, Feng S, Xia W, et al. Aspirin-exacerbated respiratory disease in China: A cohort investigation and literature review. Am J Rhinol Allergy 26:e20-e22, 2012.
26. Dursun AB, Woessner KA, Simon RA, et al. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 100:420-425, 2008.
27. Kowalski ML, and Makowska JS. Aspirin-exacerbated respiratory disease: An update on diagnosis and management. Allergy Clin Immunol 18:140-149, 2006.
28. Vaidyanathan S, Williamson PA, and Lipworth BJ. Is a positive nasal lysine-aspirin challenge test associated with a more severe phenotype of chronic rhinosinusitis and asthma? Am J Rhinol Allergy 26:e89-e93, 2012.
29. Bochenek G, Nizankowska E, and Szczeklik A. The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 51:16-23, 1996.
30. Mitsui C, Taniguchi M, Higashi N, et al. Relationship between aeroallergen sensitization and asthma severity in patients with aspirinexacerbated respiratory disease. World Allergy Organ J 5(suppl 2):S109, 2012.
31. Mascia K, Borish L, Patrie J, et al. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 94:652-657, 2005.
32. Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 24:113-124, 2003.
33. Chang JE, Chin W, and Simon R. Aspirin-sensitive asthma and upper airway diseases. Am J Rhinol Allergy 26:27-30, 2012.